← All trials
NCT03562897
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2018
- Primary completion
- Mar 1, 2020
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Catalysis SLLead sponsor
Drugs studied
Indications studied
- Adnexal Diseases
- Carcinoma
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Genital Neoplasms, Female
- Gonadal Disorders
- Neoplasms, Glandular and Epithelial
- Ovarian Diseases
- Ovarian Neoplasms
- Urogenital Neoplasms
- Female Urogenital Diseases
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.